Backbone-substituted DTPA ligands for 90Y radioimmunotherapy.

Four new bifunctional diethylenetriaminepentaacetic acid (DTPA) ligands were synthesized to provide an improved chelating agent for radioimmunotherapy with 90Y. The new DTPA ligands contained a 4-isothiocyanatobenzyl group (pSCNBz) substituted onto the carbon backbone of DTPA for use in linkage to immunoprotein. Methyl groups were strategically incorporated onto the backbone of the ligands via a peptide route to provide 2-pSCNBz-5-Me-DTPA (2) and 3-Me-6-pSCNBz-DTPA (3). Addition of these functionalities was expected to sterically hinder the release of radiometal from the chelate. A new monosubstituted ligand, 3-pSCNBz-DTPA (4), was also prepared in order to determine whether a shift in position of the linking group had an effect on the in vivo stability of the yttrium complex. Additionally, by modification of known methods, a disubstituted DTPA ligand, 2-pSCNBz-6-Me-DTPA (1), was prepared.

[1]  S. Mirzadeh,et al.  Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. , 1990, Bioconjugate chemistry.

[2]  T. Waldmann,et al.  Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. , 1989, Cancer research.

[3]  S. Kline,et al.  Synthesis of novel bifunctional chelators and their use in preparing monoclonal antibody conjugates for tumor targeting. , 1989, Journal of medicinal chemistry.

[4]  P W Doherty,et al.  Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  D. E. Simpson,et al.  Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies , 1986 .

[6]  D. Carlo,et al.  90Yttrium antiferritin--a new therapeutic radiolabeled antibody. , 1986, International journal of radiation oncology, biology, physics.

[7]  B. Sundqvist,et al.  252Cf‐Plasma Desorption Mass Spectrometry , 1985 .

[8]  B. Wessels,et al.  Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. , 1984, Medical physics.

[9]  D. Scheinberg,et al.  Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system. , 1982, Cancer research.

[10]  M. Forni,et al.  Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation. , 1980, The New England journal of medicine.

[11]  D. Solter,et al.  Tumor location detected with radioactively labeled monoclonal antibody and external scintigraphy. , 1979, Science.

[12]  A. Vølund,et al.  Removal of t-butyl and t-butoxycarbonyl protecting groups with trifluoroacetic acid. Mechanisms, biproduct formation and evaluation of scavengers. , 2009, International journal of peptide and protein research.

[13]  H. Kessler,et al.  Synthese der cyclischen Pentapeptide aus L‐Phenylalanin und Glycin , 1978 .

[14]  Ľ. Floch,et al.  Synthesis and properties of alkyl isothiocyanatocarboxylates , 1975 .

[15]  H. Brown,et al.  Selective reductions. XVIII. Fast reaction of primary, secondary, and tertiary amides with diborane. Simple, convenient procedure for the conversion of amides to the corresponding amines , 1973 .

[16]  F. C. Thompson.  A History of Platinum , 1961, Nature.

[17]  P. Durbin.  Metabolic characteristics within a chemical family. , 1959, Health physics.

[18]  H. Hart,et al.  Excretion of Yttrium and Lanthanum Chelates of Cyclohexane 1,2-Trans Diamine Tetraacetic Acid and Diethylenetriamine Pentaacetic Acid in Man , 1957, Nature.

[19]  H. Dudley.  Influence of chelates on the metabolism of radioyttrium (Y-90). , 1955, The Journal of laboratory and clinical medicine.